胶质瘤的免疫治疗进展  

Advances in immunotherapy of gliomas

作　　者：徐小珊[1] 闵彬[2] 王震[1] 刘楠[1] 刘辉[1] 涂艳阳[1] XU Xiao-Shan;MIN Bin;WANG Zhen;LIU Nan;LIU Hui;TU Yang-Yang(Department of Experimental Surgery, Tangdu Hospital, Fourth Military Medical University, Xi＇an 710038, China;Department of Out-Patient, Air Force Engineering University, Xi＇an 710050, China)

机构地区：[1]第四军医大学唐都医院实验外科,陕西西安710038 [2]空军工程大学门诊部,陕西西安710050

出　　处：《转化医学电子杂志》2017年第12期89-92,共4页E-Journal of Translational Medicine

基　　金：国家自然科学基金项目(81572983;81702458);陕西省重点研发计划(2017KW-062);陕西省社会发展科技攻关项目(2016SF-191)

摘　　要：胶质瘤作为一种颅内常见肿瘤,在过去的一个世纪,其临床治疗方面几乎没有显著的进展.免疫疗法作为一种新兴的治疗模式备受瞩目,关于胶质瘤免疫治疗的效果也有很多争议.本文就胶质瘤临床免疫治疗的现状、现阶段所存在的缺陷,以及其未来的潜力作一综述.Glioma is a common intracranial tumor. In the past century, there is little progress in the clinical treatment of gliomas. Immunotherapy, as a new treatment model, has attracted much attention. The efficacy of immunotherapy for glioma is also controversial. In this article, we will discuss the current status of clinical immunotherapy for glioma, the shortcomings of the present stage, and its future potentiality.

关 键 词：胶质瘤 免疫疗法 缺陷 潜力 

分 类 号：R739.41[医药卫生—肿瘤]